Related Experiment Videos
Melittin resistance: a counterselection for ras transformation
1Department of Microbiology and Immunology, University of Tennessee, Memphis 38163.
Abstract:
The prevalence of activated ras oncogenes in human primary tumors suggests a central role for this oncogene in human cancer. Despite its ubiquitous distribution, the biochemical role of the oncogene remains unclear, and hence attempts to control its activity have been frustrated. This study demonstrates the ability of melittin, a 26 amino acid, amphipathic peptide from bee venom, to specifically select against cells in culture that express high levels of the ras oncogene. Acquisition of resistance to increasing concentrations of melittin is accompanied by corresponding decreases in the levels of expression of the ras oncoprotein and the number of copies of the ras gene. This results in a concomitant reversion of transformed cells to a normal morphology in a strict dose-dependent manner. Melittin is a known activator of cellular phospholipase A2 (PLA2), and these results suggest an interrelationship between ras and PLA2. In addition these studies indicate that melittin preferentially hyperactivates PLA2 in ras oncogene-transformed cells, resulting in their selective destruction.
Insights
Melittin, a bee venom peptide, selectively destroys cancer cells with high levels of the ras oncogene. This targeted action reduces ras oncoprotein expression and reverts cells to normal morphology, offering a potential new cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Ras oncogenes are frequently activated in human tumors, indicating their critical role in cancer development.
- The precise biochemical function of ras oncogenes remains largely unknown, hindering therapeutic strategies.
- Melittin, a peptide from bee venom, is known to activate phospholipase A2 (PLA2).
Purpose of the Study:
- To investigate the selective anti-cancer effects of melittin on cells expressing high levels of the ras oncogene.
- To explore the relationship between melittin, ras oncogenes, and phospholipase A2 (PLA2) activity.
- To determine if melittin can revert ras-transformed cells to a normal phenotype.
Main Methods:
- Culturing cells with varying levels of ras oncogene expression.
- Treating cells with increasing concentrations of melittin.
- Measuring ras oncoprotein levels and ras gene copy number.
- Assessing cellular morphology and phospholipase A2 (PLA2) activity.
Main Results:
- Melittin specifically targeted and inhibited cells with high ras oncogene expression.
- Acquired resistance to melittin correlated with decreased ras oncoprotein levels and gene copy number.
- Melittin treatment induced a dose-dependent reversion of transformed cells to normal morphology.
- Melittin preferentially hyperactivated PLA2 in ras oncogene-transformed cells, leading to selective cell destruction.
Conclusions:
- Melittin demonstrates selective toxicity towards ras oncogene-expressing cancer cells.
- A significant interrelationship exists between ras oncogenes and PLA2 activation by melittin.
- Melittin's ability to modulate ras and PLA2 pathways offers a novel therapeutic avenue for ras-driven cancers.